Although angiotensin-converting enzyme inhibitor-related angioedema is well known, angiotensin II receptor blocker (ARB)-related angioedema has not been extensively studied because of its lower incidence. Therefore, ARB-related angioedema is likely to be overlooked in the clinical setting. We analysed the medical records of adults who had been prescribed ARB and diagnosed with angioedema between 2009 and 2015. All adults over the age of 18 years who were initially administered ARB between 1 January 2009 and 31 December 2015 were selected as participants in this study. To confirm whether the angioedema was actually due to the administration of ARB, we conducted a chart review. A total of 35 584 patients were prescribed ARB for the first time when visiting the Seoul St. Mary's Hospital during the study period. Twentyfour patients diagnosed with angioedema for other reasons prior to their first prescription of ARB were excluded from this study. ARB-related angioedema was suspected in six of 35 560 patients (0.02%) who were initially prescribed ARB during the study period. The manifestation of ARB-related angioedema ranged from several days (1/6 case) to several years (3/6 cases). Some patients continued taking ARB with intermittent antihistamine or steroid therapy. In such cases, angioedema symptoms improved but did not completely resolve.
| INTRODUCTION
Angiotensin-converting enzyme inhibitors (ACEi) are among the most widely used antihypertensive drugs. 1, 2 In addition, they are prescribed in multiple clinical settings as they offer protection against heart failure and chronic kidney disease. 3, 4 Angioedema is an adverse effect known to occur in 0.1%-0.7% of patients that are prescribed ACEi. [5] [6] [7] Although ACEi-related angioedema can manifest itself within 1 week of the initiation of ACEi in most cases, it can, in fact, manifest itself several months to several years thereafter. [8] [9] [10] For this reason, many clinicians overlook this adverse effect unless the patients pay close attention to their symptoms. If these symptoms are mistaken for allergic diseases, the drug might continue to be prescribed. In one case, a patient experienced angioedema 18 times before being diagnosed with ACEi-related angioedema. 11 This resulted from the failure of the clinician to make a definitive diagnosis. Thus, there is a high probability of underestimating the actual incidence of ACEi-related angioedema.
Although the incidence of angioedema is substantially lower in patients taking angiotensin II receptor blockers (ARB) than in those taking ACEi, ARB-related angioedema is occasionally reported.
12, 13 The definitive mechanism of ARB-related angioedema is not known, and its incidence rate is yet to be determined definitively. Presuming that the incidence of ACEi-related angioedema is underestimated, ARB-related angioedema would be even more likely to be overlooked as it has a lower incidence in the clinical setting. Therefore, clinicians must be aware of this adverse effect and take the appropriate precautions. However, it is difficult to make a definitive diagnosis of ARB (or ACEi)-related angioedema in the actual clinical setting as clinicians need to consider and exclude angioedema resulting from the intake of certain foods or other drugs. Therefore, it is difficult to conduct research on ARB-related angioedema. As such, we decided to conduct a study to screen patients who were diagnosed with angioedema at least once after their initial exposure to ARB. By conducting a chart review of patients with the manifestation of ARB-related angioedema, we analysed the extent, characteristics, progression and treatment of angioedema.
| METHODS

| Subjects
All adults over the age of 18 years who were initially administered ARB at the Seoul St. Mary's Hospital between 1 January 2009 and 31 December 2015 were selected as the subjects of this study.
| Type of ARB
We evaluated patients taking the following types of ARB: candesartan (8, 16 , 32 mg), valsartan (80, 160 mg), fimasartan (30, 60, 120 mg), irbesartan (150, 300 mg), olmesartan (10, 20 , 40 mg), telmisartan (40, 80 mg) and eprosartan (600 mg).
| Definition of angioedema
Among the patients administered ARB for the first time, we extracted all cases manifesting angioedema thereafter. The International Statistical Classification of Diseases and Related Health Problems (ICD)-10 was used to diagnose angioedema. Angioedema was defined based on the presence of ICD10 T783.000 (Angioneurotic oedema), T783.001 (Giant Urticaria), T783.002 (Quincke's oedema), T783.003 (Angioneurotic oedema with Urticaria) or T783.004 (Angioedema). We also extracted data on when the initial diagnosis was made. We excluded patients with angioedema diagnosed prior to the date when ARB was first prescribed and investigated any occurrence of angioedema that occurred after the administration of ARB.
| Direct chart review
To confirm whether the angioedema was actually due to the administration of ARB, one researcher personally conducted chart review. The possibility of angioedema due to a family history of the patient, food or food additives consumed as specified in the medical questionnaire, and any concurrently administered drugs shown in the chart were also checked. In addition, the time elapsed between the manifestation of angioedema and the administration of ARB, and the symptoms, treatment and progression of angioedema were noted.
| Privacy protection
All data extracted from the electronic medical record (EMR) were encrypted (the data in this study were anonymous, patient files were encrypted and the computer was encrypted) and stored on the corresponding author's computer. Only the corresponding author of this study was able to access these data. The corresponding author personally reviewed the charts of patients in whom angioedema occurred. Data of patients whose treatments were already completed were extracted in this study, and this would not affect the rights or physical state of the patients. Therefore, informed consent was not required. Our study was approved by the institutional review board of the Catholic University of Korea.
| RESULTS
A total of 35 584 patients were prescribed ARB for the first time when visiting the Seoul St. Mary's Hospital from 2009 to 2015 (Figure 1 ). Twenty-four patients diagnosed with angioedema for other reasons prior to their first prescription of ARB were excluded from this study. Of the remaining 35 560 patients, 0.07% (26/35 560 patients) of patients were diagnosed with angioedema after having been prescribed ARB.
| Direct chart review
Chart review was conducted for each of the 26 patients diagnosed with ARB-related angioedema for the first time.
The number of patients experiencing angioedema due to food, including alcohol, peach, cockle and sliced raw skate, was the highest at nine cases. Two patients experienced angioedema suspected to be the result of analgesics or muscle relaxants administered at an orthopaedic clinic, while one patient experienced angioedema due to CT radiocontrast medium. Six cases of angioedema that occurred during travel for personal reasons while not taking ARB were also excluded from this study. One case of ARBrelated angioedema was excluded after the patient passed an ARB provocation test. One case of angioedema that occurred while taking an ACEi was also excluded (exception case), thereby leaving a total of six patients (0.02%, 6/ 35 560) in whom ARB-related angioedema was suspected (Cases 1-6) after having excluded other possible causes (Table 1) .
| Case 1. A 77-year-old woman
This patient had a history of allergic rhinitis and had been taking prednisolone (5 mg/d) for more than 12 months for rheumatic diseases and multifocal pneumonia. The patient had also been taking losartan (50 mg) for high blood pressure for the past several years but had no particular symptoms. Nine days after having switched from losartan (50 mg) to irbesartan (150 mg), she visited the emergency room (ER) with sudden facial swelling, febrile sensation, dyspnoea, cough, sputum, neck pain and hoarseness. ARBrelated angioedema was suspected, and the patient was instructed to stop taking irbesartan. Symptoms improved following the administration of dexamethasone and intravenous pheniramine. Since that time, the patient has not taken ARB, and there has been no further manifestation of angioedema. At the time she switched to irbesartan, the patient also started to take fluvastatin (40 mg), sarpogrelate (100 mg) and coumarin (2 mg). Olmesartan (10 mg) was prescribed 12 months after the manifestation of ARBrelated angioedema. Although there was no further manifestation of angioedema, the patient was instructed to stop taking the drug because of her complaints of general weakness. The patient continues to take prednisolone as prescribed by the Rheumatology Department. Although the patient was also prescribed candesartan (4 mg) for her high blood pressure 18 months later, it was stopped because she experienced hot flushing 2 weeks thereafter. There was no record of angioedema at that time.
| Case 2. A 60-year-old man
This patient visited the hospital with sudden nausea, diarrhoea, chest discomfort, swelling, facial redness/swelling, urticaria, itching and mild dyspnoea accompanied by angioedema after having taken valsartan (80 mg) for 2 years. The patient had no allergic history, and ARBrelated angioedema was suspected as a reaction to food or other drugs was excluded. Symptoms improved following treatment with antihistamines and steroids. Candesartan (8 mg) was prescribed 8-9 months later, which the patient continues to take until now without any particular adverse event.
| Case 3. A 48-year-old woman
This patient visited the ER with a sudden rash on her back and angioedema after having taken irbesartan (300 mg) for 4 months. The patient claimed that the same symptom had repeated itself 2-3 times a month over a period of 4 months. Although the cause was not conclusively determined, the symptoms underwent a repeated cycle of improvement and aggravation when treated with medications such as antihistamines and steroids. As the patient had no history of allergy and there was the possibility of ARB-related angioedema, irbesartan was stopped. Although her angioedema completely disappeared after the cessation of irbesartan, urticaria such as a skin rash continued to occur frequently. Thus, the patient continued to visit the hospital thereafter for treatment.
| Case 4. A 57-year-old woman
This patient visited the ER with facial oedema that occurred suddenly after the patient woke up that morning. The patient had been taking candesartan (16 mg) for 3 years before switching to telmisartan (80 mg), which the patient took for 4 years thereafter. This symptom frequently repeated although it improved when antihistamines and steroids were taken. Although it is not becoming worse than before, there still is slight swelling.
| Case 5. A 69-year-old man
This patient had cerebral infarction, hypertension and hyperlipidemia and was being followed by the Department of Neurology. The patient visited the ER with angioedema accompanied by facial oedema after having taken fimasartan (60 mg) for about 4-5 months. The patient had no allergic anamnesis, and food and other drugs as the cause were ruled out. Symptoms improved after hydration and the administration of steroids. The patient continued to take fimasartan thereafter. Although his facial oedema improved, it persisted to a slight degree. One to two months later, he was diagnosed with dementia by the Department of Psychiatry. The patient did not present to the hospital thereafter with dementia.
| Case 6. A 44-year-old man
This patient had a history of hypertension and diabetes mellitus and visited the ER with angioedema, dyspnoea and redness after taking eprosartan (600 mg) for 4 years. After he was prescribed intravenous hydration, antihistamines and steroids, his symptoms improved, and then he was discharged from the ER. No follow-up was carried out as the symptoms improved, and the patient did not visit the hospital again.
| Exception case. A 64-year-old woman
For Case 7 (Exception case), angioedema was suspected after taking ACEi, but the doctor in charge did not enter a diagnosis of angioedema. Subsequently, after the ACEi was changed to ARB, a diagnosis of angioedema was entered. Hence, the diagnosis of angioedema was not recorded while taking ACEi but was recorded after taking ARB. Therefore, it was identified on direct chart review. This was a case of ACEi-related angioedema rather than ARB-related angioedema. This patient had a myocardial infarction a few years previously, and she had been undergoing treatment for hypertension and diabetes. This patient visited the ER with facial oedema and facial blushing that she had been experiencing for about a month. She had been taking lisinopril (10 mg) for 3 years. The patient was taking 21 drugs including clopidogrel. Lisinopril was stopped because of a suspicion of ACEi-related angioedema, and antihistamines without steroids were prescribed, which alleviated her symptoms. Although telmisartan (80 mg) was prescribed instead of lisinopril, the patient continued to complain of discomfort due to facial blushing although there was some improvement. All symptoms disappeared completely only after the patient also stopped taking telmisartan.
| DISCUSSION
Angiotensin-converting enzyme inhibitors and ARB are drugs for first-line treatment of high blood pressure. 14, 15 ACEi-related angioedema has an incidence in the range of 0.1%-0.2%. 16 Meanwhile, losartan-related angioedema has an incidence of about 0.1%. Although the incidence of angioedema due to ARB is lower than that due to ACEi, it is still necessary to take precautions. 17 For Case 1, four types of ARB were taken. Among these, there was no particular problem with losartan, but angioedema manifested itself upon the administration of irbesartan. This would suggest that angioedema is not a class effect for all types of ARB. However, in principle, ARB (or ACEi) is not prescribed again after the manifestation of ARB (or ACEi)-related angioedema. The recommended treatment for ACEi-related angioedema or ARBrelated angioedema is to immediately stop taking ACE inhibitors or ARB. 18 Although it is not possible to confirm the manifestation of angioedema following the administration of candesartan and olmesartan because of poor record keeping in the EMR, we suspected that angioedema was an adverse effect of these drugs based on the symptoms manifested. At any rate, further use of ARB was contra-indicated by the manifestation of angioedema due to irbesartan in Case 1. Ultimately, this patient experienced continued adverse effects due to the addition of ARB. Similarly, in Case 2, although angioedema occurred after having taken valsartan, the patient continues to take candesartan without any particular problem. However, one cannot guarantee there will be no future problems with the administration of this drug. Although angioedema usually manifests itself within several hours after the administration of ACEi (or ARB), it can also occur several years after the initial administration. [8] [9] [10] For these reasons, an immunologic, allergic or idiosyncratic reaction can be excluded, but the possibility of differences in individual patients is implied. 19 Similar to ACEiinduced angioedema, the manifestation of angioedema due to ARB-induced angioedema could have a lag time of several months. 20 Therefore, physicians may overlook the possibility of angioedema being an adverse effect of ARB. It was not easy to make a diagnosis of ARBrelated angioedema. It would have been appropriate to instruct this patient to stop taking ARB. However, if the patient needed to continue taking the drug, careful and close observation would be necessary as ARB-related angioedema can manifest itself at any time.
In Case 3, suspecting ARB-related angioedema was delayed, and the patient displayed a repeated cycle of improvement and aggravation with steroid treatment only. Symptoms finally improved conclusively when the administration of ARB was stopped. As it was not possible to diagnose ARB-induced angioedema definitively because of failure to conduct relevant clinical laboratory tests, it is a highly suspicious case as the symptoms improved following the cessation of ARB. The patient had suffered for 4 months because of a delay in diagnosis even though the symptoms recurred several times. Even if the number of cases is small and the probability is low, it is necessary to strongly suspect ARB-related angioedema if unexplained angioedema develops and all other possible causes are excluded. As it is not possible to anticipate ARB-related angioedema, there is a high possibility of under-diagnosis. Therefore, it is more important to detect and manage ARBrelated angioedema as quickly as possible in the initial stages rather than forecasting its manifestation.
In Case 4 and Case 5, a possible diagnosis of ARBrelated angioedema was overlooked. Although it cannot be definitively diagnosed as ARB-related angioedema, it should have been suspected as various other possibilities were excluded. As the patients' symptoms remained mild, it would have been advisable to try cessation of ARB. Although ARB (or ACEi)-related angioedema may be lifethreatening, the majority of cases are mild and can be treated quite easily. 8 Therefore, physicians might not pay close attention and take sufficient precautions against angioedema. If a correct diagnosis is delayed when symptoms improve readily upon steroid administration, symptoms may continue to recur. In one reported case, the cycle of angioedema improvement and aggravation continued because ARB was not stopped in spite of the angioedema. 21 In the exception case, the patient's symptoms improved after complete cessation of ACEi and ARB. Although patients with angioedema due to ACEi can experience similar symptoms with ARB alone, its frequency is substantially lower than that due to ACEi. 18 For this reason, ARB is generally recommended as a substitute drug in cases of ACEi-induced angioedema. In the exception case, the symptoms improved only when both ACEi and ARB were stopped completely. It is advisable to refrain from prescribing ARB to patients with a history of ACEi-related angioedema unless there is a definitive reason to do so. 18, 22 Angiotensin-converting enzyme inhibitors-related angioedema is not accompanied by urticaria if there is no allergic anamnesis. In this study, there was no anamnesis of allergy in most cases. In fact, the absence of anamnesis of allergy is, in itself, a powerful reason to suspect ARB (or ACEi)-related angioedema. On the contrary, if there is allergic anamnesis, it may be difficult to recognize the possibility of ARB (or ACEi)-related angioedema in many cases. In addition, if the symptoms are mild and respond well to antihistamines or steroids, the possibility of underestimating ARB-related angioedema increases even further. For these reasons, it could be recommended to consider the possibility of ARB-related angioedema irrespective of the presence of past allergic anamnesis. In Cases 1 and 4, angioedema occurred in patients with allergic anamnesis, and there was also urticaria noted in Case 3. However, there was a case of continued administration of ARB (or ACEi) with intermittent antihistamine or steroid treatment when mild ARB (or ACEi)-related angioedema was mistaken for a simple allergy.
11 Accordingly, close attention by the examining physicians is necessary. There were several limitations to this study as data were extracted retrospectively from the EMR rather than by directly observing ARB-related angioedema in an actual clinical setting. The most difficult aspect of the study was the inability to obtain further information because of poorly kept EMR records. The chart records were poorly written and did not identify all aspects of the situations. There was no choice but to make a judgement using a structured protocol. In the majority of records, ARB-related angioedema was only suspected rather than definitely diagnosed. The absence of a clear diagnostic laboratory finding to diagnose ARB-related angioedema is the greatest limitation of this research. In addition, only the data for patients with a possible diagnosis of angioedema were extracted in this study. As such, there is a possibility of under-diagnosis, considering the large number of cases in which angioedema was not specifically diagnosed although there were relevant symptoms. Moreover, as we evaluated cases from only one hospital, these findings may not be generalizable.
| CONCLUSIONS
Although ACEi-related angioedema is already well known, ARB-related angioedema is not as well known in comparison. Under-diagnosis due to its very low incidence and the lack of clear diagnostic criteria is problematic. As a result, detection of the adverse effects of this drug through close attention and accurate recognition by physicians is very important. Moreover, it is essential to warn the patients of the symptoms of angioedema, including lip oedema, at the time ACEi or ARB is prescribed.
